Given the addressable market ResMed has, alongside its market dominance, the stock has a resounding buy rating from analysts. According to Bloomberg's Analyst Recommendations, ResMed has 13 buy ratings, 0 holds, and 0 sells, with an average price target of AUD$44.64, signalling 15% upside from its last closing price.